InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Regulatory Affairs Management for Cell and Gene Therapy Market”-, By Service Type (In-house Regulatory Affairs, Outsourced Regulatory Affairs), By Application (Oncology, Rare Diseases, Genetic Disorders, Other Applications), By Therapy Type (Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy), and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034.”
Global Regulatory Affairs Management for Cell and Gene Therapy Market Size is predicted to develop a 14.2% CAGR during the forecast period for 2025-2034.
Check this Report Brochure : https://www.insightaceanalytic.com/request-sample/3084
Gene therapy is a cutting-edge medical technique that aims to treat or prevent disease by altering the genetic information within a patient’s cells. Its primary goal is to address the root causes of genetic disorders by repairing mutated genes, replacing defective genes with functional ones, or regulating gene expression. This advanced approach holds tremendous promise for treating a wide range of conditions, including hereditary disorders, certain types of cancer, and viral infections.
Recent advancements in gene therapy technologies such as CRISPR-Cas9, viral vectors, and non-viral gene delivery systems have significantly improved the precision and safety of gene editing. These innovations have reduced the risk of unintended side effects, like off-target mutations, while expanding the therapeutic possibilities. As a result, gene therapies are now capable of targeting previously untreatable diseases, offering new hope to patients with complex and rare conditions.
The future of gene therapy is increasingly being influenced by evolving regulatory frameworks, as regulatory experts play a crucial role in ensuring that these groundbreaking treatments are developed, approved, and delivered safely and effectively. As the field expands, regulatory teams are navigating complex challenges while refining guidelines and leveraging accelerated pathways to expedite patient access to life-saving therapies. This synergy between innovation and regulation is paving the way for gene therapy to become a more accessible and affordable option for patients worldwide.
In response to the growing demand for skilled professionals in cell and gene therapy (CGT) regulatory affairs, educational institutions and industry organizations are stepping up. Programs such as Drexel University’s Certificate in Regulatory Affairs for CGT and training initiatives by the Regulatory Affairs Professionals Society (RAPS) are helping bridge the expertise gap. To support the sector’s growth, companies can invest in developing or expanding training programs and certifications specifically tailored to CGT, with a focus on chemistry, manufacturing and controls (CMC), global regulatory submissions, and emerging guidelines, either by building in-house capabilities or partnering with academic institutions.
List of Prominent Players in the Regulatory Affairs Management for Cell and Gene Therapy Market:
- Novartis AG
- Amgen Inc.
- Pfizer Inc.
- Biogen Inc.
- Gilead Sciences Inc.
- Roche
- Johnson & Johnson
- Sanofi
- Bayer AG
- AstraZeneca PLC
- Lonza Group Ltd.
- Catalent, Inc.
- Thermo Fisher Scientific Inc.
- Charles River Laboratories International, Inc.
- WuXi AppTec
- IQVIA Holdings Inc.
- Parexel International Corporation
- Syneos Health, Inc.
- PPD, Inc.
- CMIC Group
Market Dynamics:
Drivers:
The growing number of cell and gene therapy (CGT) candidates in preclinical and clinical development has significantly increased the demand for specialized regulatory support. As these therapies advance toward late-stage trials and commercialization, companies must develop sophisticated regulatory strategies to navigate complex and evolving global frameworks. Personalized treatments such as autologous CAR-T cell therapies, gene-editing technologies like CRISPR, and the use of viral and non-viral delivery vectors require advanced regulatory planning to ensure compliance.
Regulatory affairs teams play a critical role in meeting stringent requirements related to Good Manufacturing Practices (GMP), Chemistry, Manufacturing, and Controls (CMC), and long-term patient follow-up, especially for first-in-class therapies. Given the high complexity and resource demands, many biotech startups and small-to-mid-size companies are choosing to outsource regulatory affairs functions. This outsourcing trend is driving the growth of the regulatory consulting and contract research organization (CRO) market, further fueling the expansion of the regulatory affairs management sector for CGT.
Challenges:
Regulatory compliance for cell and gene therapies (CGTs) is both costly and time-consuming, particularly when companies are required to manage parallel submissions to multiple global regulatory authorities. Each jurisdiction may have distinct documentation standards, review timelines, and regulatory expectations, adding to the complexity. Ensuring alignment across these diverse requirements demands significant resources and specialized expertise.
Regional Trends:
North America holds the largest share of the CGT regulatory affairs market, driven by a robust biotechnology ecosystem, strong investment in R&D, and a supportive regulatory environment. The U.S. FDA has pioneered frameworks such as the Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough Therapy status, which accelerate approval pathways for innovative treatments. The high volume of clinical trials, especially in gene therapy and CAR-T therapies, further fuels the demand for specialized regulatory support in this region. However, The Asia-Pacific region is experiencing the fastest growth in CGT regulatory affairs management. Countries like Japan, China, and South Korea are making major regulatory reforms to encourage CGT development. Japan’s Sakigake and conditional approval systems have accelerated domestic innovation, while China’s National Medical Products Administration (NMPA) is rapidly aligning with international standards.
Recent Developments:
- In Jan 2025, Bayer AG and BlueRock Therapeutics LP, A fully-owned subsidiary of Bayer AG, a clinical-stage cell therapy firm, announced plans to start a Phase III clinical study for its investigational cell therapy for Parkinson’s disease, bemdaneprocel. A major advancement in the creation of allogeneic cell-based treatments for neurodegenerative diseases, the exPDite-2 registrational trial is anticipated to start in the first half of 2025.
- In November 2023, AstraZeneca declared a partnership and investment deal with clinical-stage biotechnology company Cellectis to speed up the development of next-generation treatments in high-unmet-need fields like immunology, rare illnesses, and oncology. The collaborative agreement states that AstraZeneca will use Cellectis’ exclusive gene editing technology and production skills to create innovative cell and gene therapy medicines, enhancing AstraZeneca’s expanding product line in this area.
Segmentation of Regulatory Affairs Management for Cell and Gene Therapy Market.
Global Regulatory Affairs Management for Cell and Gene Therapy Market – By Service Type
- In-house Regulatory Affairs
- Regulatory Strategy Development
- Clinical Trial Oversight
- Post-Market Compliance
- Policy Engagement
- Others
- Outsourced Regulatory Affairs
- CMC Regulatory Affairs
- Regulatory Consulting
- Process Development Compliance
- Specialized Submissions
- Others
Global Regulatory Affairs Management for Cell and Gene Therapy Market – By Application
- Oncology
- Rare Diseases
- Genetic Disorders
- Other Applications
Global Regulatory Affairs Management for Cell and Gene Therapy Market By Therapy Type
- Cell Therapy
- Gene Therapy
- Gene-Modified Cell Therapy
Global Regulatory Affairs Management for Cell and Gene Therapy Market – By Region
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
